Literature DB >> 31851823

Interaction Energetics and Druggability of the Protein-Protein Interaction between Kelch-like ECH-Associated Protein 1 (KEAP1) and Nuclear Factor Erythroid 2 Like 2 (Nrf2).

Mengqi Zhong, Andrew Lynch, Samantha N Muellers, Stefan Jehle, Lingqi Luo, David R Hall1, Reina Iwase, James P Carolan, Megan Egbert, Amanda Wakefield, Kristina Streu, Christine M Harvey, Paula C Ortet, Dima Kozakov2, Sandor Vajda3, Karen N Allen3, Adrian Whitty3.   

Abstract

Development of small molecule inhibitors of protein-protein interactions (PPIs) is hampered by our poor understanding of the druggability of PPI target sites. Here, we describe the combined application of alanine-scanning mutagenesis, fragment screening, and FTMap computational hot spot mapping to evaluate the energetics and druggability of the highly charged PPI interface between Kelch-like ECH-associated protein 1 (KEAP1) and nuclear factor erythroid 2 like 2 (Nrf2), an important drug target. FTMap identifies four binding energy hot spots at the active site. Only two of these are exploited by Nrf2, which alanine scanning of both proteins shows to bind primarily through E79 and E82 interacting with KEAP1 residues S363, R380, R415, R483, and S508. We identify fragment hits and obtain X-ray complex structures for three fragments via crystal soaking using a new crystal form of KEAP1. Combining these results provides a comprehensive and quantitative picture of the origins of binding energy at the interface. Our findings additionally reveal non-native interactions that might be exploited in the design of uncharged synthetic ligands to occupy the same site on KEAP1 that has evolved to bind the highly charged DEETGE binding loop of Nrf2. These include π-stacking with KEAP1 Y525 and interactions at an FTMap-identified hot spot deep in the binding site. Finally, we discuss how the complementary information provided by alanine-scanning mutagenesis, fragment screening, and computational hot spot mapping can be integrated to more comprehensively evaluate PPI druggability.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31851823      PMCID: PMC8177486          DOI: 10.1021/acs.biochem.9b00943

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  87 in total

Review 1.  Protein-protein interfaces: mimics and inhibitors.

Authors:  A G Cochran
Journal:  Curr Opin Chem Biol       Date:  2001-12       Impact factor: 8.822

Review 2.  Strategies and methods in the identification of antagonists of protein-protein interactions.

Authors:  Thomas R Gadek
Journal:  Biotechniques       Date:  2003-06       Impact factor: 1.993

Review 3.  Drugs targeting protein-protein interactions.

Authors:  Patrick Chène
Journal:  ChemMedChem       Date:  2006-04       Impact factor: 3.466

4.  A detergent-based assay for the detection of promiscuous inhibitors.

Authors:  Brian Y Feng; Brian K Shoichet
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

Review 5.  Reaching for high-hanging fruit in drug discovery at protein-protein interfaces.

Authors:  James A Wells; Christopher L McClendon
Journal:  Nature       Date:  2007-12-13       Impact factor: 49.962

Review 6.  The rise of fragment-based drug discovery.

Authors:  Christopher W Murray; David C Rees
Journal:  Nat Chem       Date:  2009-06       Impact factor: 24.427

7.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours.

Authors:  Tilman Oltersdorf; Steven W Elmore; Alexander R Shoemaker; Robert C Armstrong; David J Augeri; Barbara A Belli; Milan Bruncko; Thomas L Deckwerth; Jurgen Dinges; Philip J Hajduk; Mary K Joseph; Shinichi Kitada; Stanley J Korsmeyer; Aaron R Kunzer; Anthony Letai; Chi Li; Michael J Mitten; David G Nettesheim; ShiChung Ng; Paul M Nimmer; Jacqueline M O'Connor; Anatol Oleksijew; Andrew M Petros; John C Reed; Wang Shen; Stephen K Tahir; Craig B Thompson; Kevin J Tomaselli; Baole Wang; Michael D Wendt; Haichao Zhang; Stephen W Fesik; Saul H Rosenberg
Journal:  Nature       Date:  2005-05-15       Impact factor: 49.962

8.  Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin.

Authors:  Yoo Ri Kim; Ji Eun Oh; Min Sung Kim; Mi Ran Kang; Sang Wook Park; Ji Youn Han; Hyeon Seok Eom; Nam Jin Yoo; Sug Hyung Lee
Journal:  J Pathol       Date:  2010-03       Impact factor: 7.996

9.  Identifying Interactions that Determine Fragment Binding at Protein Hotspots.

Authors:  Chris J Radoux; Tjelvar S G Olsson; Will R Pitt; Colin R Groom; Tom L Blundell
Journal:  J Med Chem       Date:  2016-04-11       Impact factor: 7.446

10.  Probing hot spots at protein-ligand binding sites: a fragment-based approach using biophysical methods.

Authors:  Alessio Ciulli; Glyn Williams; Alison G Smith; Tom L Blundell; Chris Abell
Journal:  J Med Chem       Date:  2006-08-10       Impact factor: 7.446

View more
  5 in total

1.  Importance of Binding Site Hydration and Flexibility Revealed When Optimizing a Macrocyclic Inhibitor of the Keap1-Nrf2 Protein-Protein Interaction.

Authors:  Fabio Begnini; Stefan Geschwindner; Patrik Johansson; Lisa Wissler; Richard J Lewis; Emma Danelius; Andreas Luttens; Pierre Matricon; Jens Carlsson; Stijn Lenders; Beate König; Anna Friedel; Peter Sjö; Stefan Schiesser; Jan Kihlberg
Journal:  J Med Chem       Date:  2022-02-02       Impact factor: 7.446

2.  Mining Natural Products for Macrocycles to Drug Difficult Targets.

Authors:  Fabio Begnini; Vasanthanathan Poongavanam; Björn Over; Marie Castaldo; Stefan Geschwindner; Patrik Johansson; Mohit Tyagi; Christian Tyrchan; Lisa Wissler; Peter Sjö; Stefan Schiesser; Jan Kihlberg
Journal:  J Med Chem       Date:  2020-12-18       Impact factor: 7.446

3.  Fucoxanthin Prevents 6-OHDA-Induced Neurotoxicity by Targeting Keap1.

Authors:  Wei Wu; Hui Han; Jingwangwei Liu; Min Tang; Xiaoyu Wu; Xiaojun Cao; Tiantian Zhao; Yujia Lu; Tingting Niu; Juanjuan Chen; Haimin Chen
Journal:  Oxid Med Cell Longev       Date:  2021-03-11       Impact factor: 6.543

4.  Astaxanthine attenuates cisplatin ototoxicity in vitro and protects against cisplatin-induced hearing loss in vivo.

Authors:  Benyu Nan; Zirui Zhao; Kanglun Jiang; Xi Gu; Huawei Li; Xinsheng Huang
Journal:  Acta Pharm Sin B       Date:  2021-07-10       Impact factor: 11.413

5.  Interdisciplinary Study of the Effects of Dipeptidyl-Peptidase III Cancer Mutations on the KEAP1-NRF2 Signaling Pathway.

Authors:  Sara Matić; Ana Tomašić Paić; Sandra Sobočanec; Marija Pinterić; Goran Pipalović; Monika Martinčić; Mihaela Matovina; Sanja Tomić
Journal:  Int J Mol Sci       Date:  2022-02-11       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.